Adial PHARMACEUTICALS, Inc. (ADIL) intrinsic value & 10-year financials
Adial PHARMACEUTICALS, Inc. (ADIL) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $3.49
- Market cap
- $2.3M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 146.0%
- Free cash flow (FY2025)
- —
ADIL 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$8.0M | -$11.93 | — | — | -170.7% |
| FY2024 | — | -$13.2M | -$2.72 | — | — | -323.8% |
| FY2023 | — | -$5.1M | -$3.60 | — | — | 891.4% |
| FY2022 | $143.7K | -$12.7M | -$0.51 | — | -9268.3% | 911.6% |
| FY2021 | — | -$19.4M | -$1.04 | -$12.0M | — | 817.9% |
| FY2020 | — | -$10.9M | — | — | — | -195.8% |
| FY2019 | — | -$8.6M | — | — | — | -148.4% |
| FY2018 | — | -$11.6M | — | — | — | -675.5% |
| FY2017 | — | -$1.1M | — | — | — | 207.0% |
| FY2016 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
ADIAL PHARMACEUTICALS, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
ADIAL PHARMACEUTICALS, INC. has historically struggled to out-earn its cost of capital, averaging just -14.9% ROIC.
ADIAL PHARMACEUTICALS, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
ADIAL PHARMACEUTICALS, INC. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.